Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06776432 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
A Phase 2 study of Sleep Apnea, sponsored by Shionogi Apnimed Sleep Science.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 9
- Study locations
NCT06776432: Recruiting Phase 2 study of Sleep Apnea, sponsored by Shionogi Apnimed Sleep Science.
NCT06776432 is a Phase 2 study of Sleep Apnea that is actively recruiting participants, run by Shionogi Apnimed Sleep Science. The registered enrollment target is 60 participants, below the 2,988-participant average among 36 other Sleep Apnea trials with a reported enrollment target (98% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06776432, a Phase 2 study of Sleep Apnea, is actively recruiting participants, sponsored by Shionogi Apnimed Sleep Science.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acetazolamide
- DRUG Sivopixant
- DRUG SASS-001
Study Locations (9)
Florida
- Teradan Clinical Trials - Brandon
- PharmaDev Clinical Research Institute, LLC - Miami
California
- Altman Clinical and Translational Research Institute (ACTRI) - La Jolla
Massachusetts
- Infinity Medical Research - North Dartmouth
Michigan
- John D. Dingell VA Medical Center - Detroit
Minnesota
- Mayo Clinic - Rochester
Ohio
- Intrepid Research, LLC - Cincinnati
South Carolina
- OnSite Clinical Solutions - Rock Hill
Texas
- Huntsville Research Institute LLC - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT06776432 shows while recruiting
NCT06776432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,988-participant average among 36 other Sleep Apnea trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Sleep Apnea appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06776432 lists 9 locations in 8 states (Florida, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06776432 about?
NCT06776432 is a clinical study titled "Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea". The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.
What is the current status of trial NCT06776432?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-04-02. Estimated completion is 2025-12.
What conditions does trial NCT06776432 study?
This clinical trial studies the following conditions: Sleep Apnea.
What interventions are being tested in trial NCT06776432?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG), Sivopixant (DRUG), SASS-001 (DRUG).
Who is sponsoring clinical trial NCT06776432?
This trial is sponsored by Shionogi Apnimed Sleep Science, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06776432 being conducted?
This trial has 9 study locations across California, Florida, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06776432's enrollment target sits among peer trials
60 24th of 36 higher than 12 of 36 other Sleep Apnea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sleep Apnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Endotypes Predict Response and Sequelae in OSA Patients
RECRUITING · Phase 2
-
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
RECRUITING · Phase 2
-
Research Framework Exploring Sleep Health
RECRUITING
-
Mechanisms of Prediabetic States in Sleep Apnea
RECRUITING · NA
-
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
RECRUITING · Phase 4
-
Sleep Apnea in Elderly
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI